Sophia Wang, MD
Glaucoma Specialist · Stanford, CANPI 1255674461
Payments from drug & device makers
What this record shows
This record is dominated by grants: $75,000 of the $76,908 with a category attached, or 97.5%. Alcon Research LLC accounts for 97.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $75,638 and has fallen 99.7% since, to $222 in 2025. Among glaucoma specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $2403.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$75K
- Alcon$787
- Sight Sciences, Inc.$359
- Amgen$217
- Glaukos Corporation$176
- Johnson & Johnson Surgical Vision, Inc.$101
- plus $268 from 4 others
What the payments were for
- Grants$75,00098%
- Food & beverage$1,9082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1 | $75,000 |
| Alcon | 12 | $787 |
| Sight Sciences, Inc. | 8 | $359 |
| Amgen | 2 | $217 |
| Glaukos Corporation | 2 | $176 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $101 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Boehringer Ingelheim | 1 | $83 |
| Nova Eye, Inc. | 1 | $66 |
| Ivantis, Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$147
- AcrySof IQ PanOptix$143
- Hydrus Microstent$125
How this compares
$76,908 in reported general payments places this provider in the 90th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 18 | $6,420 |
| LumiganBimatoprost | 14 | $4,327 |
| Brimonidine Tartrate | 24 | $3,338 |
| Latanoprost | 131 | $1,112 |
| Timolol Maleate | 21 | $770 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $293 |
Paid to pharmacies, not to this prescriber.
Other glaucoma specialist in Stanford
- Robert ChangStanford$105K
- Jeffrey GoldbergStanford$57K
- Yang SunStanford$2K
- Vikram ShankarStanford$1K
- Gala BeykinStanford$379
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.